Spero Therapeutics (NASDAQ:SPRO) has been assigned a $30.00 price target by research analysts at Oppenheimer in a report issued on Monday. The firm currently has a “buy” rating on the stock. Oppenheimer’s target price suggests a potential upside of 178.04% from the stock’s previous close.
SPRO has been the topic of a number of other reports. Stifel Nicolaus began coverage on Spero Therapeutics in a research note on Monday, November 27th. They issued a “buy” rating and a $26.00 price target on the stock. Cowen began coverage on Spero Therapeutics in a research note on Monday, November 27th. They issued an “outperform” rating on the stock. Finally, Bank of America began coverage on Spero Therapeutics in a research note on Monday, November 27th. They issued a “neutral” rating on the stock.
Shares of Spero Therapeutics (SPRO) traded up $0.29 during trading hours on Monday, hitting $10.79. The stock had a trading volume of 102,532 shares, compared to its average volume of 80,596. Spero Therapeutics has a 12-month low of $9.84 and a 12-month high of $15.40.
TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/12/11/oppenheimer-analysts-give-spero-therapeutics-spro-a-30-00-price-target.html.
Spero Therapeutics Company Profile
SmartPros Ltd. is engaged in provision of learning and educational solutions in content areas that target specific markets, including accounting/finance, legal, engineering, securities and insurance. The Company also provides education in banking, finance, taxation, information technology, health and safety, human resources and compliance for the general corporate market.
Receive News & Ratings for Spero Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.